BofA raised the firm’s price target on Travere Therapeutics (TVTX) to $31 from $29 and keeps a Buy rating on the shares. Investors have “re-warmed to Filspari’s outlook” following a mix of positive regulatory updates and the team’s commercial execution, says the analyst, who would still argue that the dual endothelin/angiotensin receptor antagonist “remains undervalued.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Promising Outlook for Travere Therapeutics: Buy Rating Affirmed Amid Regulatory and Market Opportunities
- Buy Rating for Travere Therapeutics Driven by sNDA Submission and Market Potential in FSGS
- Buy Rating for Travere Therapeutics Driven by Strategic Drug Developments and Regulatory Advancements
- Travere Therapeutics submits sNDA to FDA for approval of FILSPARI in FSGS
- Travere Therapeutics price target raised to $44 from $42 at JPMorgan